Antibodies targeting glypican-3 which could inhibit the recruitment of M2-polarized TAMs have shown promise for advanced HCC and have been performed in several Phase I clinical trials [108, 109]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.